Compare MPLX LP (MPLX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs TG Therapeutics Inc — how do they compare? MPLX LP trades at $56.75 (market cap $57.97B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: MPLX LP is far larger — about 7× TG Therapeutics Inc's market cap, and MPLX LP pays a 7.54% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPLX | TGTX | |
|---|---|---|
Market Cap | $57.97B | $8.26B |
Sector | Technology | Health |
52-Week High | $59.17 | $59.06 |
52-Week Low | $47.80 | $26.39 |
Enterprise Value | $82.60B | $8.50B |
Dividend Yield | 7.54% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
